Core Financial Performance - For full-year 2025, Butterfly reported total revenue of $97.6 million, up 19% from 2024, driven by growth in the core point-of-care ultrasound (POCUS) business and Butterfly Embedded [1] - Fourth-quarter revenue totaled $31.5 million, up 41% year-over-year, marking the first quarter in company history to generate positive operating cash flow [2][3] - Adjusted EBITDA loss narrowed to $3.2 million in Q4 from a $9.1 million loss a year earlier, and for full-year 2025, adjusted EBITDA loss was $26.5 million, improving from $38.9 million in 2024 [7] Growth Drivers - Growth in Butterfly Embedded was primarily attributed to the execution of the $74 million Midjourney contract, which contributed $6.8 million of Q4 revenue [5][11] - The core POCUS business saw a revenue increase of 15% year-over-year, building on a 35% growth in the prior-year fourth quarter [13] - The launch of Compass AI in Q4 was noted as a tailwind for enterprise adoption, driving over 50% growth in the enterprise pipeline since its launch [14] Future Guidance - For full-year 2026, Butterfly forecasts revenue of $117–121 million, representing approximately 20–24% growth, with an adjusted EBITDA loss of $21–25 million [4][18] - The company expects Q1 2026 revenue of $24 million to $28 million, citing seasonality, and an adjusted EBITDA loss of $8 million to $10 million [17] Strategic Initiatives - Butterfly's strategic growth plan focuses on accelerating its core POCUS business, expanding into new care settings, and extending its semiconductor ultrasound platform [8] - The company has consolidated its semiconductor platform strategy under "Butterfly Embedded," moving away from the previous "Octave" branding [12] - Butterfly aims to reach a first commercial agreement in home care in the first half of 2026, with potential revenue opportunities of $40 million to $50 million [21] Market Expansion - Management sees meaningful opportunities in 2026 as it opens markets in South America and expands across the Middle East and Asia [15] - The company has surpassed 1,000 NGO partners worldwide, indicating a strong international presence [15]

Group 1 - Butterfly Network Inc. (NYSE:BFLY) is recognized as a promising emerging technology stock due to its innovative handheld ultrasound device that connects to smartphones, utilizing patented ultrasound-on-a-chip technology [1][5] - The handheld ultrasound device is expected to make medical imaging more affordable, user-friendly, and accessible, particularly in clinics and developing countries, potentially disrupting traditional healthcare diagnostics [2][5] - TD Cowen analyst Josh Jennings has reaffirmed a Buy rating on Butterfly Network with a price target of $3.50, following positive results from the POCUS-CARE trial, which demonstrated the device's ability to reduce hospital costs and shorten patient stays [2][3] Group 2 - Jennings attributes the stock's nearly 30% decline since late July to temporary and cyclical headwinds identified during the Q2 2025 earnings call, suggesting that the pullback is excessive when considering Butterfly's long-term fundamentals [4] - With new clinical evidence supporting its technology, Butterfly Network is positioned to effectively implement its rollout strategy, reinforcing the Buy rating [5]

Financial Data and Key Metrics Changes - In 2024, Butterfly Network reported revenue of $82.1 million, representing a 25% increase year-over-year, while adjusted EBITDA loss improved by 42% to $38.9 million [9][43][49] - The fourth quarter of 2024 saw revenue of $22.4 million, the highest quarterly result in the company's history, marking a 35% increase compared to the prior year [38][39] - Gross profit for Q4 2024 was $13.7 million, a 45% increase from the prior year, with gross profit margin rising to 61% from 57% [42] Business Line Data and Key Metrics Changes - Product revenue in Q4 2024 was $14.7 million, up 45% year-over-year, driven by higher average selling prices and volume [40] - Software and other services revenue reached $7.6 million in Q4 2024, a 20% increase compared to the prior year, although the mix decreased by approximately four percentage points [40] Market Data and Key Metrics Changes - U.S. revenue in Q4 2024 was $14.5 million, a 32% increase year-over-year, while international revenue increased by 19% to $5.5 million [39] - The launch of the iQ3 device accounted for 50% of overall sales in units and 58% of probe revenue in 2024 [13] Company Strategy and Development Direction - Butterfly Network aims to expand its digital ecosystem and enhance accessibility to ultrasound technology, targeting a vision where every healthcare provider has a personal imaging device [10][11] - The company is focusing on scaling its core POCUS business and expanding into new markets, including home care and veterinary applications [22][23][29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving a revenue target of $96 million to $100 million for 2025, representing approximately 20% growth, while maintaining fiscal discipline [49] - The company is optimistic about the potential of its HomeCare and Octiv businesses, which are expected to contribute significantly to future revenue [66][68] Other Important Information - Butterfly Network raised $81.7 million from a follow-on offering in January 2025, providing a bridge to cash flow independence [48] - The company has signed 21 partners in its Butterfly Garden initiative, with six expected to go commercial in 2025 [24] Q&A Session Summary Question: Update on confidence level for $500 million revenue target - Management is bullish about growth initiatives and believes they are on track to achieve the long-term revenue target [62][64] Question: Steps required to transition HomeCare from pilot to revenue - The transition involves training on-site personnel and utilizing telemedicine for scalability, with a 90-day process for training [75][79] Question: Update on wearable technology development - The wearable is in development, with a focus on building market demand before launching the product [88][90] Question: Details on HomeCare pilot and patient involvement - 18 nurses were trained across two facilities, with a pilot designed for 200 patients, and no readmissions reported so far [92][95] Question: Hardware developments and iQ station update - The company is actively working on next-generation hardware and the iQ station, which will expand into the lower-end cart business [97][100]